{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:01:24Z","timestamp":1790625684172,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,28]],"date-time":"2027-09-28T00:00:00Z","timestamp":1822089600000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA259168"],"award-info":[{"award-number":["R01CA259168"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.nucmedbio.2026.109680","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:31:31Z","timestamp":1789666291000},"page":"109680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploration of the cysteine protease trapping approach to prolong tumor retention of antifolate targeted radionuclide therapeutics"],"prefix":"10.1016","volume":"162-163","author":[{"given":"Sadie","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audif\u00e1s-Salvador","family":"Matus-Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian M.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Rikhtechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Brake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana Sherkat","family":"Sadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika A.","family":"Cone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobin","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jered C.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109680_bb0005","series-title":"StatPearls","article-title":"Epithelial ovarian cancer","author":"Arora","year":"2025"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0010","series-title":"Cancer facts & figures 2024","author":"American Cancer Society","year":"2024"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109680_bb0015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.5306\/wjco.v11.i11.868","article-title":"Liquid biopsy in ovarian cancer: catching the silent killer before it strikes","volume":"11","author":"Feeney","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109680_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/14737159.4.2.157","article-title":"Signature of a silent killer: expression profiling in epithelial ovarian cancer","volume":"4","author":"Le Page","year":"2004","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109680_bb0025","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12905-022-02016-1","article-title":"Pathways to ovarian cancer diagnosis: a qualitative study","volume":"22","author":"Lawson-Michod","year":"2022","journal-title":"BMC Womens Health"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109680_bb0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/AOG.0000000000001196","article-title":"Ovarian cancer treatment and survival trends among women older than 65 years of age in the United States, 1995-2008","volume":"127","author":"Lin","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109680_bb0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20181965","article-title":"Toward a better understanding of folate metabolism in health and disease","volume":"216","author":"Zheng","year":"2019","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109680_bb0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jn\/129.4.779","article-title":"Folate metabolism and requirements","volume":"129","author":"Bailey","year":"1999","journal-title":"J Nutr"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","article-title":"Emerging roles for folate receptor FOLR1 in signaling and cancer","volume":"33","author":"Nawaz","year":"2022","journal-title":"Trends Endocrinol Metab"},{"issue":"6220","key":"10.1016\/j.nucmedbio.2026.109680_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0055","series-title":"FOLR1","author":"Atlas","year":"2024"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109680_bb0060","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/bjc.2017.118","article-title":"One-carbon metabolism in cancer","volume":"116","author":"Newman","year":"2017","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109680_bb0065","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1002\/onco.13603","article-title":"Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment","volume":"26","author":"Alsdorf","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0070","first-page":"781","article-title":"Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer","volume":"5","author":"Ricciardi","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0075","series-title":"FDA approves mirvetuximab soravtansine-gynx for FRa positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer","author":"Administration, U.S.F.a.D.","year":"2024"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109680_bb0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal Biochem"},{"issue":"D1","key":"10.1016\/j.nucmedbio.2026.109680_bb0085","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: the universal protein knowledgebase in 2021","volume":"49","author":"The UniProt, C","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254532","article-title":"Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer","volume":"14","author":"Mai","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00249","article-title":"Prospects in folate receptor-targeted radionuclide therapy","volume":"3","author":"M\u00fcller","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2022.214702","article-title":"Folate-based radiotracers for nuclear imaging and radionuclide therapy","volume":"470","author":"Wagner","year":"2022","journal-title":"Coord Chem Rev"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109680_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/bc9500709","article-title":"Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging","volume":"7","author":"Wang","year":"1996","journal-title":"Bioconjug Chem"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109680_bb0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2967\/jnumed.107.045856","article-title":"SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate","volume":"49","author":"M\u00fcller","year":"2008","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109680_bb0115","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00259-006-0111-9","article-title":"Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting","volume":"33","author":"M\u00fcller","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109680_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061508","article-title":"Development of folate receptor-targeted PET radiopharmaceuticals for tumor imaging-a bench-to-bedside journey","volume":"12","author":"Boss","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0125","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejmech.2019.05.068","article-title":"Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor","volume":"177","author":"Fan","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2967\/jnumed.119.231282","article-title":"Development of improved tumor-residualizing, GRPR-targeted agents: preclinical comparison of an endolysosomal trapping approach in agonistic and antagonistic constructs","volume":"61","author":"Zhang","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109031","article-title":"Exploration of the utilization of irreversible cysteine protease inhibitor in FAP-targeted radiopharmaceuticals design to increase tumor residence time","volume":"146-147","author":"Brake","year":"2025","journal-title":"Nucl Med Biol"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109680_bb0140","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/acs.bioconjchem.2c00214","article-title":"Examination of charge modifications of an endolysosomal trapping inhibitor in an antagonistic NTSR1-targeted construct for colon cancer","volume":"33","author":"Fan","year":"2022","journal-title":"Bioconjug Chem"},{"issue":"80","key":"10.1016\/j.nucmedbio.2026.109680_bb0145","doi-asserted-by":"crossref","first-page":"11268","DOI":"10.1039\/C8CC05982A","article-title":"Increasing time on target: utilization of inhibitors of cysteine cathepsins to enhance the tumor retention of receptor-targeted agents","volume":"54","author":"Fan","year":"2018","journal-title":"Chem Commun (Camb)"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109680_bb0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0167-4838(99)00263-0","article-title":"Lysosomal cysteine proteases: more than scavengers","volume":"1477","author":"Turk","year":"2000","journal-title":"Biochim Biophys Acta Protein Struct Mol Enzymol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1194\/jlr.R062760","article-title":"Trafficking of glycosylphosphatidylinositol anchored proteins from the endoplasmic reticulum to the cell surface","volume":"57","author":"Mu\u00f1iz","year":"2016","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109680_bb0160","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.addr.2004.01.010","article-title":"Folate receptor endocytosis and trafficking","volume":"56","author":"Sabharanjak","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ph10030072","article-title":"Folate receptor-positive gynecological cancer cells: in vitro and in vivo characterization","volume":"10","author":"Siwowska","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109680_bb0170","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/mp200511t","article-title":"Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast","volume":"9","author":"Reber","year":"2012","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0175","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/acs.molpharmaceut.1c00932","article-title":"Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities","volume":"19","author":"Bene\u0161ov\u00e1","year":"2022","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cells8030264","article-title":"Cysteine cathepsins and their extracellular roles: shaping the microenvironment","volume":"8","author":"Vidak","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109680_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109680_bb0190","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1016\/S0021-9258(18)32429-3","article-title":"Amino acid sequence of porcine spleen cathepsin D light chain","volume":"258","author":"Takahashi","year":"1983","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109680_bb0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(85)81136-4","article-title":"Amino acid sequence of human liver cathepsin B","volume":"181","author":"Ritonja","year":"1985","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109680_bb0200","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/bc0200430","article-title":"Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical","volume":"13","author":"Leamon","year":"2002","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0205","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/bc050323q","article-title":"Synthesis and in vitro\/in vivo evaluation of novel 99mTc(CO)3-folates","volume":"17","author":"M\u00fcller","year":"2006","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3344\/kjp.2018.31.3.145","article-title":"Three principles for radiation safety: time, distance, and shielding","volume":"31","author":"Kim","year":"2018","journal-title":"Korean J Pain"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109680_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030345","article-title":"Beyond small molecules: antibodies and peptides for fibroblast activation protein targeting radiopharmaceuticals","volume":"16","author":"Sun","year":"2024","journal-title":"Pharmaceutics"},{"issue":"10\u221211","key":"10.1016\/j.nucmedbio.2026.109680_bb0220","first-page":"1513","article-title":"E-64 [L-trans-epoxysuccinyl-leucyl-amido(4-guanidino)butane] and related epoxides as inhibitors of cysteine proteinases","volume":"40","author":"Barrett","year":"1981","journal-title":"Acta Biol Med Ger"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109680_bb0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1097-0282(1999)51:1<99::AID-BIP11>3.0.CO;2-R","article-title":"Structural basis of inhibition of cysteine proteases by E-64 and its derivatives","volume":"51","author":"Matsumoto","year":"1999","journal-title":"Biopolymers"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25030698","article-title":"A review of small molecule inhibitors and functional probes of human cathepsin L","volume":"25","author":"Dana","year":"2020","journal-title":"Molecules"},{"issue":"2015","key":"10.1016\/j.nucmedbio.2026.109680_bb0235","article-title":"Cathepsin B is a new drug target for traumatic brain injury therapeutics: evidence for E64d as a promising lead drug candidate","volume":"6","author":"Hook","year":"2015","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109680_bb0240","first-page":"672","article-title":"In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64","volume":"9","author":"Tamai","year":"1986","journal-title":"Aust J Pharm"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109680_bb0245","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.119.237818","article-title":"In vivo instability of (177)Lu-DOTATATE during peptide receptor radionuclide therapy","volume":"61","author":"Lubberink","year":"2020","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109680_bb0250","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.124.269132","article-title":"First-in-human serum stability studies of [(177)Lu]Lu-AMTG: a step toward improved GRPR-targeted radiopharmaceutical therapy","volume":"66","author":"Felber","year":"2025","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109680_bb0255","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.nucmedbio.2015.06.006","article-title":"Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy","volume":"42","author":"Haller","year":"2015","journal-title":"Nucl Med Biol"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109680_bb0260","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109680_bb0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug Resist Updat"},{"issue":"38","key":"10.1016\/j.nucmedbio.2026.109680_bb0270","doi-asserted-by":"crossref","first-page":"15180","DOI":"10.1073\/pnas.1308827110","article-title":"Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition","volume":"110","author":"Wibowo","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0275","series-title":"Modern nutrition in health and disease: Eleventh edition","author":"Ross","year":"2012"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0280","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-nutr-072610-145133","article-title":"Mechanisms of membrane transport of folates into cells and across epithelia","volume":"31","author":"Zhao","year":"2011","journal-title":"Annu Rev Nutr"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109680_bb0285","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1021\/acs.molpharmaceut.4c01324","article-title":"Enhanced retention of NTSR1-targeted radionuclide therapeutics via covalent inhibitors in pancreatic, colorectal, and prostate cancer models","volume":"22","author":"Zhang","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2026.109680_bb0290","article-title":"Ischemia-reperfusion injury reduces kidney folate transporter expression and plasma folate levels","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109680_bb0295","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1535-7163.MCT-13-0422-T","article-title":"177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy","volume":"12","author":"Reber","year":"2013","journal-title":"Mol Cancer Ther"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512600079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512600079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:30:36Z","timestamp":1790623836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980512600079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":59,"alternative-id":["S096980512600079X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109680","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of the cysteine protease trapping approach to prolong tumor retention of antifolate targeted radionuclide therapeutics","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109680"}}